Aspen Neuroscience
aspenneuroscience.com
Cell & Gene Therapy
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in "Cell Stem Cell"
Read more
Report
Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in
Peer-reviewed findings describe reproducible manufacturing, leading-edge genomic quality controls and preclinical evidence supporting clinical dev...
Read more
Report
Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in "Cell Stem Cell"
Read more
Report
Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson's Disease
Read more
Report
Aspen Neuroscience: $115 Million Series C Raised To Advance Personalized Cell Therapy Pipeline
Aspen Neuroscience has closed a $115 million Series C financing round to accelerate clinical development of its personalized autologous cell therapy programs, marking one of the company's most significant funding milestones to date. The San Diego-based bi
Read more
Report
Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting
Aspen Neuroscience, Inc. announced its participation in "Illuminating the Future," the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, to be held in Hong Kong June 11-14.
Read more
Report
Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson
Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) therapy being studied in patients with moderate to advan
Read more
Report
Show more news